You are here: Industry Insights > Sciwind

News List

Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 2b Clinical Trial Evaluating XW003, its Lead GLP-1 Drug Candidate, for the Treatment of Obesity prnasia
January 18, 2022
Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the initiation of patient dosing...
Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients prnasia
December 10, 2021
Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the completion of patient...
Sciwind Biosciences Appoints Dr. Weidong Zhong as Chief Strategy Officer and President of its US Subsidiary prnasia
July 13, 2021
Hangzhou Sciwind Biosciences Co., Ltd. announced the appointment of Dr. Weidong Zhong, former co-founder and executive of Terns Pharmaceuticals, as Chief Strategy Officer and President of its US subsidiary, Sciwind Biosciences USA.
Sciwind's Investigational New Drug Approved for NASH Trial prnasia
March 01, 2021
Hangzhou Sciwind Biosciences Co., Ltd. today announced that XW003, a potential candidate for the treatment of non-alcoholic steatohepatitis (NASH), has been approved by China NMPA for clinical trial.
Sciwind Biosciences Secures US$37 Million Series B Financing prnasia
February 19, 2021
Hangzhou Sciwind Biosciences Co., Ltd. (Sciwind), a clinical-stage, fast-growing biopharmaceutical company focusing on research and development of innovative biologics, today announced the closing of an US$37 Million series B financing.